Treatment of Cognitive and Sensorimotor Deficits in Parkinson's Disease With High Definition Transcranial Direct Current Stimulation

Starting soon · Not applicable · Has a placebo group

Conditions studied: PARKINSON DISEASE (Disorder)

In brief

The purpose of this research study is to examine the effects of transcranial Direct Current Stimulation (tDCS) on verbal retrieval and cognition and sensorimotor control and to determine if tDCS can be used as a way to improve retrieval, sensory, and motor abilities in individuals with Parkinson's disease (PD).

Key facts

Study ID

NCT07534397

Run by

The University of Texas at Dallas

People needed

20

Starts

2026-08-01

Expected to finish

2027-10-31

Last updated by the study team

2026-06-26

Who can join

Age: 50 and older, up to 90. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Diagnosed with PD having a verbal fluency deficit based on neuropsychological test (T-score < 40 or a T-score <-1.0 SD below the average T-score): Semantic Object Retrieval Test (SORT), COWAT (both letter and category fluency), Boston Naming Test (BNT), Rey Auditory Verbal Learning Test (RAVLT)
• 50 - 90 years old
• Capable of understanding and signing an informed consent (able to answer consent comprehension questions)
• Fluent in speaking and reading English

You may not qualify if…

• A potentially study-confounding, tDCS-contraindicated, or EEG-contraindicated psychological, neuropsychiatric, neurological, or other medical issues:
• Montreal Cognitve Assessment (MOCA) score <23, unless an accompanying study partner/caregiver is with them and we can obtain the written consent of both the participant and the participant's accompanying study partner/caregiver (i.e., the participant's spouse, adult child, parent, or adult sibling);
• history of seizures;
• unexplained episodes of loss of consciousness (as these may be related to brain alterations or epilepsy);
• suffering from severe or frequent headaches;
• unstable or uncontrolled neuropsychiatric illness;
• severe traumatic brain injury (based on the Ohio State TBI Identification; Method);
• brain tumor; stroke; present drug abuse/misuse;
• brain tumor;
• serious or life-threatening diseases, including congestive heart failure, chronic obstructive pulmonary disease, or active malignancy;
• Huntington's disease;
• stroke;
• cranial implants or skull defects that affect tDCS administration;
• implanted brain medical devices, including, deep brain stimulators (DBS);
• implanted pacemakers;
• any electrically, magnetically, or mechanically activated implants;
• cardiac, neural, or medication implants;
• vascular clips or other electrically sensitive support systems in the brain;
• damaged skin at the sites of stimulation (the device should only be used on healthy, intact skin, as wounds may alter resistance to current);
• skin conditions such as dermatitis, psoriasis, or eczema;
• pregnant women;
• diagnosis of just dysarthria;
• Use of medications that interact with or potentially interact with tDCS or EEG effects:
• anti-convulsants;
• carbamazepine;

Where it is running

• Callier Clinical Center, The University of Texas at Dallas — Richardson, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.